Protagonist Therapeutics (PTGX) Stock Statistics & Valuation Metrics

Protagonist Therapeutics has a market cap or net worth of $10.04B. The enterprise value is $7.93K.

Protagonist Therapeutics has 64,708,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

Protagonist Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.23%.

The current PE Ratio of Protagonist Therapeutics is 127.3. Protagonist Therapeutics’s PEG ratio is 0.29.

In the last 12 months, Protagonist Therapeutics had revenue of 46.02M and earned -130.15M in profits. Earnings per share was -2.05.

In the last 12 months, operating cash flow was 131.20M and capital expenditures 975.00K, giving a free cash flow of 132.17M billion.

Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Protagonist Therapeutics upcoming earnings date is Nov 5, 2026, After Close (Confirmed).

Protagonist Therapeutics as a current ratio of 12.71, with Debt / Equity ratio of 1.10%

In the past 12 months, Protagonist Therapeutics has paid 838.00K in taxes.

Protagonist Therapeutics EV to EBITDA ratio is -42.43, with an EV/FCF ratio of 96.90.

Protagonist Therapeutics has $782.58M in cash and marketable securities with $9.22M in debt, giving a net cash position of $773.36M billion.

Gross margin is 99.86%, with operating margin of -343.63%, and net profit margin of -282.83%.

The average price target for Protagonist Therapeutics is $162.45, which is 11.43% higher than the current price. The consensus rating is Strong Buy